This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takatsuki, F. Articles by Akiyama, Y. Search for Related Content PubMed Articles by Takatsuki, F. Articles by Akiyama, Y.

Interleukin 6 Perfusion Stimulates Reconstitution of the Immune and Hematopoietic Systems after 5-Fluorouracil Treatment

Central Research Laboratories, Ajinomoto Co., Inc., Kawasaki-ku, Kawasaki 210 [F. T., A. O., C. S., Y. M., D. E., Y. A.], and Institute for Molecular and Cellular Biology, Osaka University, Suita, Osaka 565 [T. H., T. K.], Japan

Effects of interleukin 6 (IL-6) on the functional capacity of the immune and hematopoietic systems in 5-fluorouracil (5-FU)-treated mice were determined. IL-6 (5 x 10⁴ units/mouse/day) was administered s.c. for 7 days by implantation of an osmotic pump, since it was demonstrated that a much higher increase in the primary response to sheep RBC was observed by administration of slowly released rather than daily s.c. injection of IL-6. IL-6 perfusion significantly augmented anti-sheep RBC antibody responses depressed by 5-FU (150 mg/kg) treatment. IL-6 also was shown to stimulate hematological recovery in mice treated with 5-FU. Namely, IL-6 perfusion accelerated the recovery of the number of hematopoietic stem cells, granulocyte-macrophage progenitors, and mature neutrophils in the spleen, although IL-6 did not stimulate the recovery of the neutrophil count in blood. Recovery of the platelet count in blood was stimulated by IL-6. Furthermore, it was found that the endogenous IL-6 level in serum increased after 5-FU treatment, which suggests that IL-6 may play some role in the recovery of the immune and hematopoietic systems. Finally, we examined the effect of IL-6 on the survival of mice treated with a higher dosage of 5-FU (300 mg/kg). IL-6 perfusion produced a distinct increase in survival rate at Day 30 (74% versus 28%). It is of note that the number of bacteria (identified as Escherichia coli) cultured from the spleen and the liver decreased in IL-6-perfused mice. This IL-6-induced effect was accompanied by enhancement of an oxidative burst response. Moreover, the anti-E. coli antibody titer in serum was higher in IL-6-perfused mice than in control mice. These results suggest the possible use of IL-6 for stimulating the reconstitution of the immune and hematopoietic systems after chemotherapy treatment.

¹ To whom requests for reprints should be addressed.

Received 10/13/89. Revised 2/ 8/90.

This article has been cited by other articles:

				H. Sasaki, K. Balto, N. Kawashima, J. Eastcott, K. Hoshino, S. Akira, and P. Stashenko Gamma Interferon (IFN-{gamma}) and IFN-{gamma}-Inducing Cytokines Interleukin-12 (IL-12) and IL-18 Do Not Augment Infection-Stimulated Bone Resorption In Vivo Clin. Vaccine Immunol., January 1, 2004; 11(1): 106 - 110. [Abstract] [Full Text] [PDF]

				R. V. Gardner, E. McKinnon, C. Poretta, and L. Leiva Hemopoietic Function After Use of IL-1 with Chemotherapy or Irradiation J. Immunol., August 1, 2003; 171(3): 1202 - 1206. [Abstract] [Full Text] [PDF]

				M. Jin, H. Jeon, H. J. Jung, B. Kim, S. S. Shin, J. J. Choi, J. K. Lee, C.-Y. Kang, and S. Kim Enhancement of Repopulation and Hematopoiesis of Bone Marrow Cells in Irradiated Mice by Oral Administration of PG101, a Water-Soluble Extract from Lentinus lepideus Experimental Biology and Medicine, June 1, 2003; 228(6): 759 - 766. [Abstract] [Full Text] [PDF]

				F. Bracho, M. D. Krailo, V. Shen, S. Bergeron, V. Davenport, W. Liu-Mares, B. R. Blazar, A. Panoskaltsis-Mortari, C. van de Ven, R. Secola, et al. A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities Clin. Cancer Res., January 1, 2001; 7(1): 58 - 67. [Abstract] [Full Text]

				H Akahori, K Shibuya, M Ozai, M Ida, K Kabaya, T Kato, and H Miyazaki Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice Stem Cells, November 1, 1996; 14(6): 678 - 689. [Abstract]

				T. Kanda, J. E. Wilson McManus, R. Nagai, S. Imai, T. Suzuki, D. Yang, B. M. McManus, and I. Kobayashi Modification of Viral Myocarditis in Mice by Interleukin-6 Circ. Res., May 1, 1996; 78(5): 848 - 856. [Abstract] [Full Text]